贝利尤单抗治疗系统性红斑狼疮继发难治性极重度血小板减少1例

doi:10.35541/cjd.20230532

Chinese Journal of Dermatology ›› 2026, e20230532.doi: 10.35541/cjd.20230532

• Case Reports • Previous Articles Next Articles

Belimumab for the treatment of systemic lupus erythematosus complicated by refractory extremely severe thrombocytopenia: a case report

Liao Xiaoling, Zhao Cheng, Lei Ling, Wen Jing

Department of Rheumatology and Clinical Immunology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China

Received:2023-09-14 Revised:2026-04-15 Online:2026-03-11 Published:2026-07-31
Contact: Wen Jing E-mail:wenjinghello@126.com
Supported by:
2020 Guangxi Medical and Health Appropriate Technology Development and Promotion Application Project（S2020039）

Abstract

Liao Xiaoling, Zhao Cheng, Lei Ling, Wen Jing. Belimumab for the treatment of systemic lupus erythematosus complicated by refractory extremely severe thrombocytopenia: a case report[J]. Chinese Journal of Dermatology,2026,e20230532. doi:10.35541/cjd.20230532

References ［7］

［1］	Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for systemic lupus erythematosus［J］. Arthritis Rheumatol, 2019,71（9）:1400⁃1412. DOI: 10.1002/art. 40930.
［2］	徐亮, 王元, 陈顺乐. 低剂量泼尼松治疗系统性红斑狼疮血小板减少的疗效观察［J］. 中华皮肤科杂志, 2005,38（6）:386⁃387. DOI: 10.3760/j.issn:0412⁃4030.2005.06.021.
［3］	龙现明, 蔡成森, 周欣, 等. 系统性红斑狼疮继发难治性血小板减少的临床特征分析［J］. 中华风湿病学杂志,2020,24（3）:170⁃174. DOI: 10.3760/cma.j.issn.1007⁃7480.2020.03.005.
［4］	Mahévas M, Michel M, Weill JC, et al. Long⁃lived plasma cells in autoimmunity: lessons from B⁃cell depleting therapy［J］. Front Immunol, 2013,4:494. DOI: 10.3389/fimmu.2013.00494.
［5］	Mahévas M, Azzaoui I, Crickx E, et al. Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: results from a prospective phase 2b trial［J］. Haematologica, 2021,106（9）:2449⁃2457. DOI: 10.3324/haematol.2020.259481.
［6］	Shipa M, Embleton⁃Thirsk A, Parvaz M, et al. Effectiveness of belimumab after rituximab in systemic lupus erythematosus : a randomized controlled trial［J］. Ann Intern Med, 2021,174（12）:1647⁃1657. DOI: 10.7326/M21⁃2078.
［7］	Atisha⁃Fregoso Y, Malkiel S, Harris KM, et al. PhaseⅡ randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis［J］. Arthritis Rheumatol, 2021,73（1）:121⁃131. DOI: 10.1002/art.41466.

Belimumab for the treatment of systemic lupus erythematosus complicated by refractory extremely severe thrombocytopenia: a case report

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［7］

Related Articles 0

Metrics

Comments

Recommended 10